BF Biosciences Limited today announced a planned leadership transition, following a notice submitted to the Pakistan Stock Exchange (PSX). According to the notice, Mrs. Akhter Khalid Waheed, Founding Chairperson and Chief Executive Officer of BF Biosciences Limited, has decided to step down from her role as Chief Executive Officer, effective December 31, 2025. The Board of Directors, in its emergent meeting held on December 19, 2025, formally accepted her resignation and placed on record its deep appreciation for her visionary leadership and invaluable contributions to the establishment, growth, and long-term success of the Company. Under her stewardship, BF Biosciences evolved into a recognized name in Pakistan’s pharmaceutical sector, marked by sustained growth, operational excellence, and strategic expansion. Following the recommendation of the HR & Remuneration Committee, the Board has approved the appointment of Mr. Muhammad Farhan Rafique as Chief Executive Officer, effective January 1, 2026. Mr. Farhan Rafique has been associated with BF Biosciences Limited as Chief Operating Officer, where he played a pivotal role in executing key strategic initiatives under the leadership of Mrs. Akhter Khalid Waheed. His contributions include leading the Company’s brownfield expansion, supporting a successful Initial Public Offering (IPO), and driving digital transformation projects across operations. With over 14 years of experience in the pharmaceutical industry, Mr. Rafique has held various leadership roles and brings deep operational insight, strategic vision, and execution capability to his new role. The Board expressed confidence that Mr. Rafique’s appointment will ensure continuity of leadership and further strengthen the Company’s growth trajectory, while building on the strong foundation laid by its founding CEO. BF Biosciences Limited remains committed to advancing healthcare solutions, strengthening its market presence, and creating long-term value for its stakeholders.
